Latest

2 stories

Hide weekly roundups

Tuesday, August 25

Quarterly updateAnavex Life Sciences Corp.

Anavex reports fiscal Q3 2026 results, updates progress on Alzheimer's, Rett, Fragile X programs

Anavex has moved completed Alzheimer's trial data to its FDA IND, sought an FDA meeting on Rett syndrome pediatric inclusion, and plans a Fragile X IND submission in September 2026.

SEC filing

Thursday, July 30

Quarterly updateAnavex Life Sciences Corp.

Anavex updates Alzheimer's regulatory strategy, reports Q2 fiscal 2026 results

The company said it opened a new FDA IND for early Alzheimer's disease and is prioritizing blarcamesine programs in Alzheimer's, Rett syndrome and Fragile X syndrome.

SEC filing